REG - Premaitha Health PLC - Directorate change

Yourgene HealthAnnouncement

03/10/2018 07:05

RNS Number : 7612C
Premaitha Health PLC
03 October 2018
 


Premaitha Health PLC
("Premaitha" or the "Company")
 
Directorate change
 
Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing ("NIPT"), announces that, further to the announcement made by the Company on 20 September 2018, Mr Hayden Jeffreys has been appointed as Group Commercial Director to the Company following completion of customary director due diligence. Mr Jeffreys will take up his position on the Board of Premaitha with immediate effect.
 
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Mr Hayden William Jeffreys (aged 42):
 



Current Appointments


Appointments in the last 5 years




Cambridge DX Limited


Delta Biologicals Srl








Diamedix Inc








Drew Scientific Inc








Erba Diagnostics Inc








Erba Diagnostics Mexico S.A.








Erba Mannheim Gmbh








Immunovision Inc








Jas Diagnostics Inc








Lumora Limited



 
There is no further information regarding Mr Jeffreys required to be disclosed under the AIM Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
Enquiries
 



Premaitha Health plc


Tel: +44 (0) 161 667 6865




Lyn Rees, Chief Executive Officer


 




Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing


 




investors@premaitha.com


 




 


 




Cairn Financial Advisers LLP (Nomad)


Tel: +44 (0) 20  7213 0880




Liam Murray / James Caithie


 




 


 




finnCap (Broker)


Tel: +44 (0) 20 7220 0500




Geoff Nash / Matthew Radley (Corporate Finance)


 




Tim Redfern (Corporate Broking)


 




 


 




Vigo Communications


Tel: +44 (0) 20 7390 0234




Ben Simons / Fiona Henson / Antonia Pollock








premaitha@vigocomms.com


 



 
 
About Premaitha
 
Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group's primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.
 
Premaitha's IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample - which contains traces of placental DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.
 
Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.
 
In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.
 
Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUGGAAUUPRGQP